The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells.

The orphan G protein-coupled receptor 37 (GPR37) is homologous to endothelin (ETB-R) and bombesin (GRP-R, NMB-R) receptors. The present study was undertaken to determine the expression and functional significance of GPR37 in human multiple myeloma (MM). We found that GPR37 was lowly expressed in MM cell adhesion model and highly expressed in proliferating cells. In vitro, meddling with the expression of GPR37 affected the CAM-DR by regulating the ability of cell adhesion and the activity of Akt and ERK in MM cells. Further studies indicated the positive role of GPR37 in the proliferation of MM cells.

[1]  Hermann Einsele,et al.  Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma , 2012, British journal of haematology.

[2]  C. Chung,et al.  Fibronectin-mediated adhesion rescues cell cycle arrest induced by fibroblast growth factor-1 by decreased expression of P21cip/waf in human chondrocytes , 2005, In Vitro Cellular & Developmental Biology - Animal.

[3]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[4]  R. Kerbel,et al.  Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.

[5]  C. Beam,et al.  Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. , 2006, Cancer research.

[6]  C. Croce,et al.  Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Aggarwal,et al.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model (Molecular Cancer Therapeutics (2009) 8, (959-970)) , 2009 .

[8]  C. Lacombe,et al.  Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma , 2002, Oncogene.

[9]  R. Kerbel,et al.  Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.

[10]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[11]  L. Pallanck,et al.  Parkin A Multipurpose Neuroprotective Agent? , 2003, Neuron.

[12]  P. Tan,et al.  Parkin Enhances the Expression of Cyclin-dependent Kinase 6 and Negatively Regulates the Proliferation of Breast Cancer Cells* , 2010, The Journal of Biological Chemistry.

[13]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[14]  W. Dalton,et al.  Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.

[15]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[16]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[17]  W. Dalton,et al.  Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death , 2003, Oncogene.

[18]  D. Katenkamp,et al.  Intercellular substances in Hodgkin's lymphomas. Ultrastructural investigations. , 1978, Virchows Archiv A Pathological Anatomy and Histology.

[19]  T. Satou,et al.  Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. , 2011, Cytokine.

[20]  Y. Shiozawa,et al.  Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. , 2010, Blood.

[21]  R. Jove,et al.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.

[22]  A. Cress,et al.  Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype , 2011, Molecular Cancer Therapeutics.

[23]  A. McBride,et al.  Proteasome inhibitors in the treatment of multiple myeloma , 2013, Expert review of anticancer therapy.

[24]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[25]  B. Aggarwal,et al.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model , 2009, Molecular Cancer Therapeutics.

[26]  G. Tocchini-Valentini,et al.  Absence of the GPR37/PAEL receptor impairs striatal Akt and ERK2 phosphorylation, ΔFosB expression, and conditioned place preference to amphetamine and cocaine , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  G. Tocchini-Valentini,et al.  Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. , 1998, Genomics.

[28]  G. Tocchini-Valentini,et al.  Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Lonial,et al.  PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. , 2007, Future oncology.

[30]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[31]  W. Dalton,et al.  Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines1 , 2002, The Journal of Immunology.

[32]  W. Dalton,et al.  Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. , 2006, Blood.

[33]  Hermann Einsele,et al.  Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. , 2011, Blood.

[34]  Shaji K. Kumar,et al.  Thalidomide and lenalidomide in the treatment of multiple myeloma. , 2006, European journal of cancer.

[35]  H. Müller-Hermelink,et al.  Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. , 2008, Blood.

[36]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[37]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[38]  P. Richardson,et al.  Multiple myeloma , 2009, The Lancet.

[39]  M. Levrero,et al.  Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. , 2008, Blood.

[40]  N. Halama,et al.  The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications , 2011, British journal of haematology.

[41]  S. Jagannath,et al.  The current status and future of multiple myeloma in the clinic. , 2010, Clinical lymphoma, myeloma & leukemia.

[42]  Charles P. Lin,et al.  Defining the role of TORC1/2 in multiple myeloma. , 2011, Blood.

[43]  Jin Han,et al.  CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. , 2012, Immunology letters.